tbuckley/cabot-search huggingface dataset:
Yes‐Associated Protein in Kupffer Cells Enhances the Production of Proinflammatory Cytokines and Promotes the Development of Nonalcoholic Steatohepatitis
Authors: Kyoungsub Song, Hyunjoo Kwon, Chang Han, Weina Chen, Jinqiang Zhang, Wenbo Ma, Srikanta Dash, Chandrashekhar R. Gandhi, Tong Wu
Journal: Hepatology (2019)

Background and Aims Yes‐associated protein (YAP) plays an important role in hepatocarcinogenesis, although the potential role of YAP in non‐neoplastic liver diseases remains largely unknown. We report herein that YAP in Kupffer cells (KCs) enhances the production of proinflammatory cytokines and promotes the development of nonalcoholic steatohepatitis (NASH). Our data show that the expression of YAP is significantly increased in KCs of wild‐type mice fed a high‐fat diet (HFD). Approach and Results We generated mice with macrophage/monocyte‐specific deletion of YAP (YAP ϕKO ) or Toll‐like receptor 4 (TLR4; TLR4 ϕKO ), and animals were fed an HFD or treated with lipopolysaccharide (LPS). Our data showed that YAP ϕKO mice fed an HFD exhibited lower serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels and less hepatic inflammation when compared to their littermate controls. LPS treatment induced accumulation of YAP in KCs in vitro and in mice, which was prevented by macrophage/monocyte‐specific deletion of TLR4 (TLR4 ϕKO ). LPS transcriptionally activates YAP through activator protein 1 in macrophages/KCs. LPS‐induced YAP further enhances expression of proinflammatory cytokines (including monocyte chemoattractant protein 1, tumor necrosis factor alpha, and interleukin 6) through YAP association with the TEA domain–binding motif in the promoter region of inflammatory cytokines. Forced overexpression of active YAP (YAP5SA) in KCs enhanced the production of proinflammatory cytokines. Treatment of HFD‐fed mice with verteporfin inhibited KC activation, reduced liver inflammation, and decreased serum ALT/AST levels. Analyses of liver tissues from NASH patients reveal that YAP is increased in KCs and that level of YAP in human liver tissues is positively correlated with expression of proinflammatory cytokines. Conclusions This study describes an important role of YAP in KCs for regulation of liver inflammation in NASH. Our findings suggest that inhibition of YAP may represent an effective therapeutic strategy for NASH treatment.
Human Plasmacytoid Dendritic Cell Line (PMDC05) Established from a Patient with CD4+CD56+ Acute Leukemia.
Authors: Miwako Narita, Nozomi Tochiki, Shigeo Hashimoto, Asuka Sekiguchi, Norihiro Watanabe, Ayumi Yokoyama, Anri Saitoh, Junjiro Tsuchiyama, Toshio Yano, Masayoshi Masuko, Ken Toba, Tatsuo Furukawa, Yoshifusa Aizawa, Masuhiro Takahashi
Journal: Blood (2005)
Abstract 879: Aldehyde Dehydrogenase Activator 1 (Alda-1) Attenuates Coronary Endothelial Dysfunction-Mediated Cardiac Damage in ALDH2*2 Diabetic Mice
Authors: Guodong Pan, Haiyan Pang, Mandar Deshpande, Suresh Palaniyandi
Journal: Circulation Research (2019)

Background: Endothelial dysfunction plays a critical role in the pathogenesis of diabetic complications. Diabetes-mediated reactive aldehydes like 4-hydroxy-2-nonenal (4HNE) are associated with endothelial cell impairment. Aldehyde dehydrogenase (ALDH) 2, a mitochondrial enzyme which detoxifies 4HNE, protects heart function against diabetic cardiomyopathy. Nearly 600 million East Asians have a point mutation of ALDH2, termed as ALDH2*2, which causes an intrinsic low ALDH2 activity. Previously, we reported an aggravated coronary endothelial dysfunction in ALDH2*2 mutant knock-in mice (ALDH2*2 mice) with diabetes. Aldehyde dehydrogenase activator 1 (Alda-1) is the only known activator for both normal ALDH2 and mutant ALDH2*2. We hypothesized that Alda-1 could protect endothelial cells (ECs) from hyperglycemia induced coronary endothelial dysfunction in diabetic ALDH2*2 mice. Methods and Results: Diabetes was induced by streptozotocin injection (150 mg/kg) to ALDH2*2 mice. Alda-1 (10 mg/kg/d, DM-A) or vehicle (DM-V) was delivered through mini-pumps for 3 weeks after diabetes. We found an increased left ventricular pressure (59.9±18.7 vs 66.4±20.1 mmHg) and a decreased perfusion pressure (89.4±8.1 vs 83.6±12.1 mmHg) in Langendorff hearts from DM-A (DM-V vs DM-A, p&lt;0.05, respectively). In heart sections, CD31+ (127.2±22.3 vs 270.5±53.7 /mm 2 ) and eNOS+ cells (136.2±22.8 vs 366.7±33.6 /mm 2 ) were increased while apoptosis (1117.5±303.6 vs 727.1±254.8 /mm 2 ) and 4HNE+ (515.8±8.3 vs 181.7±72.5 /mm 2 ) cells were reduced in DM-A (DM-V vs DM-A, p&lt;0.05, respectively). Direct perfusion of 4HNE to Langendorff hearts from control ALDH2*2 mice (4HNE) increased perfusion pressure (Δ3.18±0.5 vs Δ36.6±7.7 mmHg), arteriole closure (8.3±0.4 vs 39.8±3.7 /mm 2 ), and decreased eNOS+ cells (2877.1±117.3 vs 37.5±5.6 /mm 2 ) (Sham vs 4HNE, p&lt;0.05). One-day Alda-1 (10 mg/kg) pre-treatment before 4HNE perfusion (A-4HNE) decreased perfusion pressure (Δ7.1±1.7 mmHg), number of closed arterioles (22.4±4.8 /mm 2 ), and increased eNOS+ (878.0±121.3 /mm 2 ) cells (4HNE vs A-4HNE, p&lt;0.05, respectively). Conclusion: Alda-1 protects hyperglycemia mediated 4HNE induced coronary endothelial dysfunction and thereby cardiac tissue in ALDH2*2 diabetic mice.
Complexity in Assessing the Benefit vs Risk of Vaccines
Authors: H. Cody Meissner
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gene Expression Profiling (GEP) Analysis of Plasma Cells (PC) Obtained From MRI-Defined Focal Lesions (FL) Under CT-Guided Fine-Needle Aspiration Provides Better Risk Stratification in Patients with Multiple Myeloma
Authors: Qing Zhang, Pingping Qu, Emily Hansen, Christoph Heuck, Saad Usmani, Bijay Nair, Sarah Waheed, Yazan Alsayed, Antje Hoering, John Crowley, John D Shaughnessy, Bart Barlogie
Journal: Blood (2011)
A Bortezomib-Based Regimen Offers Excellent Outcomes In Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: Phase II Results
Authors: John Koreth, Haesook T. Kim, Paulina B. Lange, Bhavjot Bindra, Philippe Armand, Corey S. Cutler, Vincent T. Ho, Brett Glotzbecker, Jerome Ritz, Bruce R Blazar, Robert J. Soiffer, Joseph H. Antin, Edwin P. Alyea
Journal: Blood (2013)
Demographics, Treatment Outcomes and Resource Utilization Among Patients Hospitalized with Adult Onset Hemophagocytic Lymphohistiocytosis (HLH): A Nationwide Analysis
Authors: Prabhjot Singh Bedi, Manoj P Rai, Samanjit Kaur Kandola, Justin D. Kaner, Mark Mujer, Calvin Abro, Ikponmwosa Enofe, Shilpa Kavuturu, Nishant Tageja, Heather Laird-Fick, Marwan S Abougergi, James B. Bussel, Stanley M. Marks
Journal: Blood (2018)
Induction of house officers
Authors: M. McBride
Journal: BMJ (1992)

Nursing time must be allowed for cleaning and disinfecting sigmoidoscopes during a list, and more than one sigmoidoscope may be required.Nursing time is required for correctly maintaining sigmoidoscopes and disinfection equipment weekly to keep all equipment in good condition and prevent cross infection.Sigmoidoscopy can be performed by general practitioners, but they must recognise that it is costly with important health and safety aspects.
Distribution and Outcome According to Cytogenetics in 502 Paediatric AML Patients Treated in Study AML-BFM 98.
Authors: Christine von Neuhoff, Jutta Bradtke, Martin Zimmermann, Jean-Pierre Bourquin, David Betts, Jan Stary, Zuzana Zemanova, Michael N Dworzak, Dirk Reinhardt, U. Creutzig
Journal: Blood (2008)
Implementation of an enhanced recovery program framework in medical oncology.
Authors: Brittany C Campbell, Yvette Ong, Jarrod Eska, Sharon Mathai, Noel Mendez, Maroof Olanigan, Susy Varghese, Mark Waits, Marina C. George
Journal: Journal of Clinical Oncology (2019)

66 Background: Enhanced recovery programs (ERPs) apply multi-modal approaches to manage symptoms, decrease complications, and reduce length of stay (LOS). Widely adopted in surgical settings, there is limited evidence of their implementation in non-surgical patient cohorts. An ERP was implemented in a medical oncology population at a National Cancer Institute-designated comprehensive cancer center. The aim of this quality improvement initiative was to evaluate the implementation of an enhanced recovery framework and determine feasibility in medical oncology. Methods: Enhanced recovery in medical oncology (ERMO) was implemented using Plan, Do, Study, Act methodology. Implementation included introduction of integrative medicine, opioid sparing alternatives, fluid and nutrition management, and functional mobility. Outcome measures included symptom distress as measured by the Edmonton Symptom Assessment Scale (ESAS), return to intended oncologic therapy (RIOT), LOS, and opioid use, evaluated from January 2017 through April 2018. Results: A total of 50 patients were evaluated during the program implementation, and compared with 49 control patients retrospectively reviewed prior to ERMO implementation. Average LOS for ERMO patients was 7.3 days compared to 5.5 days for the control group. Time to RIOT averaged 18.9 days for control patients (n = 30) versus 20.8 days for ERMO patients (n = 17). Nineteen patients (38%) had a reduction in morphine equivalent daily dose (MEDD) from admission to discharge, with an average MEDD of 328.47 milligrams per patient. Conclusions: ERMO as a framework is feasible. The patient reported outcomes such as ESAS and RIOT, and barriers to implementation, including participant engagement and patient pain management perceptions, should be evaluated in the context of larger clinical trials.
Arsenic Trioxide Encapsulated in MSC-Derived Extracellular Vesicles: A Novel Therapy for aGVHD in Mice
Authors: Xiao Liu, Ya-Nan Wang, Gao-chao Zhang, Yan Su, Qiu-sha Huang, Chen-Cong Wang, Hai-Xia Fu, Yun He, Qian-Ming Wang, Xiang-Yu Zhao, Xiao-Su Zhao, Meng Lv, Ying-Jun Chang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Xiaohui Zhang
Journal: Blood (2018)
Spatial variability in the reproduction number of Ebola virus disease, Democratic Republic of the Congo, January–September 2019
Authors: Kenji Mizumoto, Amna Tariq, Kimberlyn Roosa, Jun Kong, Ping Yan, Gerardo Chowell
Journal: Eurosurveillance (2019)

The ongoing Ebola virus disease epidemic (August 2018─October 2019) in the Democratic Republic of the Congo, has been exacerbated by deliberate attacks on healthcare workers despite vaccination efforts. Using a mathematical/statistical modelling framework, we present the quantified effective reproduction number (Rt) at national and regional levels as at 29 September. The weekly trend in Rt displays fluctuations while our recent national-level Rt falls slightly above 1.0 with substantial uncertainty, which suggests improvements in epidemic control.
Chronic Myeloid Leukemia Incidence Based Estimates of Hematopoietic Stem Cell Numbers per Person
Authors: Tomas Radivoyevitch, Brian P. Hobbs, Yasunobu Nagata, Jacob Scott, Asha Kallianpour, Takuya Sakaguchi, Jaroslaw P. Maciejewski, Yasushi Miyazaki
Journal: Blood (2018)
Perspectives on cancer care delivery from oncology patients who experienced unplanned acute care events.
Authors: Tara L. Kaufmann, Katharine A. Rendle, Erin Aakhus, Andrea Bilger, Peter Edward Gabriel, Vivek Nimgaonkar, Arnav Shah, Rebecca Trotta, Frances Barg, Justin E. Bekelman
Journal: Journal of Clinical Oncology (2019)

201 Background: Unplanned acute care is debilitating and burdensome for patients with advanced cancer and their caregivers. There is a pressing need to understand how available evidence-based practices (EBPs) to reduce acute care 1) align with the needs and priorities of patients and 2) are best implemented within large health systems. We are conducting a mixed methods study to assess patient- provider- and system-level factors that shape the decision to seek acute care during active cancer treatment in order to select and adapt EBPs for implementation. Here we present data from patients’ perspectives. Methods: Purposive sampling approach to identify solid tumor cancer patients on active treatment with unplanned acute care events at a large health system from Aug 2018-Jan 2019. We conducted semi-structured interviews to elicit patients’ perspectives on factors that shape their decision to seek acute care and to inform intervention strategies. Results: Forty-nine patients participated in this study. We identify several patient factors that intersect with the decision to seek care: self-management behaviors, guilt, negative ED perception, safety concerns, and trust. Patients attempt self-management prior to contacting their oncology team, which introduces variability in the duration and severity of reported symptoms. Delay is related to patients’ guilt for burdening their oncology team and to provider accessibility. Patients describe a high symptom threshold to seek care that is often coupled with a negative perception of the ED, but do prefer in-person evaluation for new and distressing symptoms for safety. They express a high level of trust in the oncology team and relative distrust of non-oncology providers. Conclusions: Our data suggest a conceptual model for patient factors that drive unplanned acute care. Patients identify three areas for improvement: 1) enhanced peer support and education to manage uncertainty about cancer treatment; 2) accessible portals for patient-clinician communication; and 3) home or clinic-based after-hours oncology symptom management. Interventions to target these needs should address patients’ emotional concerns and be well integrated within the oncology team.
Utilizing technology for malnutrition screening and referrals to nutrition services.
Authors: Susan Franco, Corrine Hanson, Glenda Woscyna, Jana Wells, Meghan McLarney
Journal: Journal of Clinical Oncology (2019)

284 Background: The incidence of disease-related malnutrition in oncology patients ranges from 40-80%. This is the highest of all hospital patient groups. Malnutrition is associated with decreased quality of life, increased healthcare costs and intolerance to treatment. Screening for nutrition risk is often lacking in outpatient settings. Electronic health records could be utilized to improve the delivery of validated nutrition screening tools such as the Malnutrition Screening Tool (MST) in outpatient oncology settings. Methods: We designed a pilot project (Feb-July 2018) to administer the MST for outpatient oncology patients seen at the Fred and Pamela Buffett Cancer Center (FPBCC) using an electronic medical record system. “Best Practice Alerts” (BPAs) were used to notify the nursing staff of a patient with a screen that was positive for nutrition risk (MST score ≥3). The BPA recommended a referral to nutrition services; nursing staff could choose to “order” or “do not order" a Nutrition Consult. Results: A total of 2,672 patients received MST screening during the pilot. Out of these, 223 (8%) had a positive screen for nutrition risk; 197 of these were eligible for a nutrition services referral. A BPA “fired” 152 times out of 197 eligible patients (77%). Of the197 eligible patients, 58 (29%) were actually referred to nutrition services. Of these 58 referrals, 43 (74%) were triggered based on a BPA, while the remaining referrals were received outside of a BPA. BPAs failed to fire 45/197 times (23%). Conclusions: An EHR-based nutrition screening system to increase referrals in patients identified at nutrition risk in an outpatient oncology setting was effective for 29% of eligible patients. Barriers encountered included failures in technology as well as human factors. During the pilot it was discovered that the BPA was firing in a location in the chart where the nurse did not regularly work. There was not a consistent message as to the goals and outcomes during the pilot which resulted in lack of awareness by nurses to respond to the nutrition risk score. Utilizing an EHR-based nutrition screening tool is an effective way to identify patients at risk and refer them to appropriate resources in a timely and efficient way.
Pre-Operative Transfusion Reduces Serious Adverse Events in Patients with Sickle Cell Disease (SCD): Results From the Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) Randomised Controlled Multicentre Clinical Trial
Authors: Jo Howard, Moira Malfroy, Llewelyn Charlotte, Louise Choo, David Rees, Isabeau Walker, Tony Johnson, Louise Tillyer, Karin Fijnvandraat, Melanie Kirby-Allen, Renate Hodge, Shilpi Purohit, Sally C. Davies, Lorna M Williamson
Journal: Blood (2011)
Genomics as a Tool for Antigen Discovery in Allogeneic Stem Cell Transplantation: Identification of the Minor Antigen T4A through Donor/Patient Polymorphism Disparities
Authors: Paul Armistead, Shoudan Liang, Sijie Lu, Cornelis A.M. van Bergen, J.H.F. Falkenburg, Jeffrey J. Molldrem
Journal: Blood (2008)
Effects of interleukin-2 in immunostimulation and immunosuppression
Authors: Jonathan G. Pol, Pamela Caudana, Juliette Paillet, Eliane Piaggio, Guido Kroemer
Journal: The Journal of Experimental Medicine (2019)

Historically, interleukin-2 (IL-2) was first described as an immunostimulatory factor that supports the expansion of activated effector T cells. A layer of sophistication arose when regulatory CD4+ T lymphocytes (Tregs) were shown to require IL-2 for their development, homeostasis, and immunosuppressive functions. Fundamental distinctions in the nature and spatiotemporal expression patterns of IL-2 receptor subunits on naive/memory/effector T cells versus Tregs are now being exploited to manipulate the immunomodulatory effects of IL-2 for therapeutic purposes. Although high-dose IL-2 administration has yielded discrete clinical responses, low-dose IL-2 as well as innovative strategies based on IL-2 derivatives, including "muteins," immunocomplexes, and immunocytokines, are being explored to therapeutically enhance or inhibit the immune response.
Cleaved Caspase-3 Transcriptionally Regulates Angiogenesis-Promoting Chemotherapy Resistance
Authors: Antoine Bernard, Sandy Chevrier, Françoise Beltjens, Magalie Dosset, Etienne Viltard, Anaïs Lagrange, Valentin Derangère, Alexandra Oudot, François Ghiringhelli, Bertrand Collin, Lionel Apetoh, Olivier Feron, Suzie Chen, Laurent Arnould, Frédérique Végran, Romain Boidot
Journal: Cancer Research (2019)

Caspases are well known for their role in apoptosis. Recently, nonapoptotic roles of caspases have been identified, however, these noncanonical roles are not well documented and the mechanisms involved are not fully understood. Here, we studied the role of cleaved caspase-3 using human- and mouse-proficient caspase-3 cancer cell lines and human-deficient caspase-3 cancer cells. Cleaved caspase-3 functioned as a transcription factor and directly bound to DNA. A DNA-binding domain was identified in the small subunit of caspase-3 and an active conformation was essential for caspase-3 transcriptional activity. Caspase-3 DNA binding enhanced angiogenesis by upregulating the expression of proangiogenic genes and by activating pathways that promoted endothelial cell activation. Some proapoptotic genes were downregulated in caspase-3-proficient cells. Inhibiting caspase-3 increased the efficacy of chemotherapy and decreased spontaneous tumor development. These data highlight a novel nonapoptotic role of caspase-3 and suggest that cleaved caspase-3 could be a new therapeutic target in cancer. SIGNIFICANCE: These findings report a noncanonical function of caspase-3 by demonstrating its ability to transcriptionally regulate the VEGFR pathway.
Short-term dialysis catheter versus central venous catheter infections in ICU patients: a post hoc analysis of individual data of 4 multi-centric randomized trials
Authors: Niccolò Buetti, Stéphane Ruckly, Jean-Christophe Lucet, Olivier Mimoz, Bertrand Souweine, Jean-François Timsit
Journal: Intensive Care Medicine (2019)
The effect of clinical pathways utilization on total cost of care for the treatment of prostate cancer.
Authors: Karen Ann Sereday, David C. Boulware, Vasanth Kailasam, JuQing Shi, Diane L. Blazevich, Jason M. Burkett, Sandra C. Stewart, Julio M. Pow-Sang, Peter Anthony Johnstone, Dana Elise Rollison, Karen K. Fields
Journal: Journal of Clinical Oncology (2019)

20 Background: Moffitt Cancer Center (MCC) has developed evidence-based cancer care pathways which are integrated into the Electronic Health Record (EHR). We retrospectively compared the 1 year (yr) total cost of care in patients (pts) with newly diagnosed prostate cancer (PCA) treated at MCC based on EHR tool utilization and pathway alignment. Methods: Using existing Cancer Registry data, we retrospectively identified all pts presenting with newly diagnosed PCA between 7/1/2015-6/30/2017 who received all 1st course treatment (tx) at MCC. Pts direct costs were tracked for 1 yr from the Cancer Registry “date of 1st contact.” Tx was categorized as either radiation (RT) +/- hormone tx (HT), surgery (S) +/- HT, active surveillance only (ASO), HT only, palliative care, chemotherapy (CT), or mixed (a combination of S, RT, or CT). Pathway alignment was either electronically tracked through the EHR pathway tool or determined through manual chart review for pts tx’ed off the pathway tool. Results: 477 pts met inclusion criteria, including men with: low or favorable intermediate (n=259); unfavorable intermediate, high, or very high (n=186); and metastatic (n=32) risk group PCA. The majority (n=396, 83%) had tx in alignment with a pathway. The major tx modalities on pathway were S-HT (n=139), RT-HT (n=113), or ASO (n=110) and off pathway were RT-HT (n=52, 64%), S-HT (n=10), or ASO (n=9). Overall, treatment in alignment with a pathway was significantly associated with lower 1 yr total cost compared to off pathway tx (p &lt;0.001) with a mean difference of $5,500 per pt yr. Conclusions: Clinical pathway alignment was significantly associated with less aggressive therapy and lower 1 yr cost of care for PCA pts treated at MCC. Cost of care was highly associated with tx modality selected. Further analyses are needed to understand the association between pathway alignment, patient risk factors and tx modality selection.